Abstract:Background: Gastrointestinal symptoms are common in Coronavirus Disease 2019 (COVID-19), related to infection of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) of intestinal cells through the angiotensin converting enzyme 2 (ACE2) receptor in the brush border. Also, patients are treated with multiple antibiotics. Therefore, an increase in gut dysbiosis and in the prevalence of Clostridium difficile infection (CDI) is expected in patients with COVID-19. Methods: A PubMed search was conducted using the terms "gut microbiota," "gut mycobiota," "dysbiosis" AND "COVID-19"; "Clostridium difficile," "Clostridioides difficile" AND "COVID-19"; "probiotics," "bacteriotherapy AND COVID-19." Only case series, observational and experimental studies were included. Results: A total of 384 papers were retrieved and 21 fulfilled selection criteria. Later, a new paper was identified, thus 22 papers were reviewed. Main findings: (1) gut bacterial dysbiosis has been found in fecal samples of COVID-19 patients, with enrichment of opportunistic organisms and decrease of beneficial commensals such as Faecalibacterium prausnitizii. Dysbiosis is related to inflammatory markers and illness severity. (2) There is evidence for abnormal gut barrier and bacterial translocation with a negative impact in the lungs. (3) Fungal dysbiosis correlating with pulmonary mycobiota, has also been found. (4) There is controversy in the CDI rates among COVID-19 patients versus controls and pandemic versus prepandemic era. (5) There is no available evidence yet to support bacteriotherapy in COVID-19. (6) Fecal microbiota transplantation (FMT) has been proposed for COVID-19, although there is no evidence to support it. Also, FMT can be safely used during the pandemic for CDI if strict screening protocols for donors and fecal product are implemented. Conclusions: In COVID-19 there is bacterial and fungal dysbiosis that correlates with systemic and pulmonary inflammation, and illness severity. Further investigations are warranted to determine the efficacy of bacteriotherapy and FMT for modulating gut dysbiosis in COVID-19.

Coronavirus Disease (COVID-19) Caused by (SARS-CoV-2) Infections: A Real Challenge for Human Gut Microbiota

Gut Microbiota and COVID-19: Potential Implications for Disease Severity

Gut Microbiome Disruption Following SARS-CoV-2: A Review

COVID-19 and the Human Gut Microbiome: An Under-Recognized Association

Impact of SARS-CoV2 infection on gut microbiota dysbiosis

Untangling the link between the human gut microbiota composition and the severity of the symptoms of the COVID‐19 infection

Coronavirus infection and gut microbiota

The Faecal Metabolome in COVID-19 Patients is Altered and Associated with Clinical Features and Gut Microbes

Gut microbiota in COVID-19: new insights from inside

The relationship between gut microbiota and COVID-19 progression: new insights into immunopathogenesis and treatment

COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens

Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions

COVID-19 and Gut Microbiota: A Potential Connection

Alterations of the Gut Microbiota in Patients with Coronavirus Disease 2019 or H1N1 Influenza.

Gut microbiota and COVID‐19: A systematic review

Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential

Bacterial and Fungal Gut Dysbiosis and Clostridium difficile in COVID-19: A Review

Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID

Microbiota and Its Impact on the Immune System in COVID-19—A Narrative Review

Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity

Gut Microbiota Dysbiosis–Immune Hyperresponse–Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches